Riccardo Ricciardi, MD
Urology · Bayside, NYNPI 1558307256
Payments from drug & device makers
Across 295 payments — averaging $44.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$3K
- Coloplast$1K
- Astellas Pharma US Inc$1K
- Atricure, Inc.$831
- Sumitomo Pharma America, Inc.$649
- Johnson & Johnson$602
- plus $5K from 33 others
What the payments were for
- Consulting fees$1,0908%
- Speaking & faculty fees$1,53012%
- Travel & lodging$8867%
- Food & beverage$9,29471%
- Education$3713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 16 | $3,480 |
| Coloplast | 15 | $1,303 |
| Astellas Pharma US Inc | 42 | $1,293 |
| Atricure, Inc. | 5 | $831 |
| Sumitomo Pharma America, Inc. | 32 | $649 |
| Johnson & Johnson | 22 | $602 |
| Teleflex LLC | 14 | $589 |
| Bayer | 23 | $541 |
| Boston Scientific | 13 | $506 |
| Pfizer | 17 | $329 |
| Axonics, Inc. | 5 | $308 |
| Dendreon Pharmaceuticals LLC | 9 | $270 |
| Accord Healthcare, Inc. | 3 | $247 |
| Myovant Sciences Inc. | 13 | $247 |
| Ferring Pharmaceuticals Inc. | 8 | $175 |
| Cvrx, Inc. | 1 | $164 |
| Medtronic | 1 | $161 |
| Verity Pharmaceuticals Inc. | 8 | $153 |
| Tolmar, Inc. | 2 | $151 |
| Urovant Sciences Inc | 9 | $150 |
| AstraZeneca | 1 | $133 |
| AbbVie(2 entities) | 5 | $110 |
| Valencia Technologies Corporation | 1 | $109 |
| Myriad Genetic Laboratories, Inc. | 6 | $109 |
| Olympus America Inc. | 4 | $91 |
| SRS Medical Systems, Inc. | 1 | $75 |
| Telix Pharmaceuticals | 3 | $68 |
| Sun Pharmaceutical Industries Inc. | 3 | $65 |
| Urogen Pharma, Inc. | 2 | $44 |
| Amgen | 2 | $39 |
| Civco Medical Instruments | 1 | $30 |
| Immunitybio, Inc. | 1 | $29 |
| Progenics Pharmaceuticals, Inc. | 1 | $22 |
| Ambu Inc. | 1 | $21 |
| Argon Medical Devices, Inc. | 1 | $19 |
| Calyxo, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Mission Pharmacal Company | 1 | $14 |
| Dentsply IH Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$3,313
- TITAN$997
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$673
- ATRICLIP LAA EXCLUSION SYSTEM$660
- XTANDI$259
- UroLift System$238
- CAMCEVI$210
- Axonics$178
- Barostim Neo System$164
- LigaSure$161
- LYNPARZA$133
- ELIGARD$131
- JATENZO$131
- rezum Generator$125
- Xofigo$120
- eCoin Device Kit$109
- AMS$104
How this compares
$13,171 in reported general payments places this provider in the 80th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lupron DepotLeuprolide Acetate | 76 | $427,784 |
| OrgovyxRelugolix | 50 | $134,603 |
| MyrbetriqMirabegron | 126 | $73,518 |
| GemtesaVibegron | 71 | $57,998 |
| Abiraterone Acetate | 14 | $24,911 |
| Tamsulosin Hcl | 611 | $9,062 |
| Testosterone | 33 | $5,194 |
| Trospium Chloride | 91 | $4,143 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 148 | $3,321 |
| Solifenacin Succinate | 44 | $2,171 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 176 | $1,889 |
| Tadalafil | 22 | $1,807 |
| CefuroximeCefuroxime Axetil | 162 | $1,591 |
| Silodosin | 21 | $1,380 |
| Finasteride | 148 | $1,357 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLupron Depot | $110 | $427,78476 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $649 | $192,600121 claims |
| Astellas Pharma US IncMyrbetriq | $1,293 | $73,518126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 952 urology providers in New York.
Other urology in Bayside
- Christopher PieczonkaSyracuse$31.2M
- Guarionex DecastroNew York$5.7M
- Mitchell EfrosGarden City$4.2M
- James McKiernanNew York$4.1M
- William HuangNew York$3.9M
- Jed KaminetskyMiddle Village$3.5M
- Evan GoldfischerPoughkeepsie$3.1M
- Gennady BratslavskySyracuse$2.5M
- Ashutosh TewariNew York$2.5M
- Manish ViraNew Hyde Park$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.